KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Other Operating Expenses (2016 - 2025)

Sarepta Therapeutics has reported Other Operating Expenses over the past 10 years, most recently at $399.4 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses changed N/A year-over-year to $399.4 million; the TTM value through Dec 2025 reached $842.2 million, up 1546.28%, while the annual FY2023 figure was $102.0 million, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2025 was $399.4 million at Sarepta Therapeutics, up from $151.5 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $399.4 million in Q4 2025 and troughed at $31.6 million in Q1 2022.
  • A 5-year average of $119.7 million and a median of $102.0 million in 2021 define the central range for Other Operating Expenses.
  • On a YoY basis, Other Operating Expenses climbed as much as 919.47% in 2021 and fell as far as 69.91% in 2021.
  • Year by year, Other Operating Expenses stood at $102.0 million in 2021, then plummeted by 69.0% to $31.6 million in 2022, then soared by 222.57% to $102.0 million in 2023, then plummeted by 49.84% to $51.2 million in 2024, then surged by 680.68% to $399.4 million in 2025.
  • Business Quant data shows Other Operating Expenses for SRPT at $399.4 million in Q4 2025, $151.5 million in Q3 2025, and $153.2 million in Q2 2025.